The FDA’s decision to nix Pfizer (PFE)’s development of a new osteoarthritis drug, tanezumab, reveals some serious errors of judgment among management. Especially when you couple it with the company’s confession that it will not proceed with a study of the antipsychotic Geodon in children in part because it cannot meet an FDA deadline.
